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Background/aim: To evaluate the periocular changes due to topical bimatoprost and latanoprost use and to investigate their effects on
the lacrimal drainage system.
Materials and methods: All participants (69 eyes of 43 patients, 52 eyes of 26 controls) were classified into three groups: bimatoprost
(0.03%) users, latanoprost (0.005%) users, and healthy controls. Each patient was examined before prostaglandin therapy, and then at
the first, third, sixth, and twelfth month of therapy. Palpebral fissure height, upper eyelid crease, and levator function were measured,
and lacrimal system drainage irrigation was performed. Periocular hyperpigmentation and upper eyelid sulcus were also examined.
Results: No significant change was identified in palpebral fissure height or levator function in any group. However, in upper eyelid
crease, among bimatoprost users, a statistically significant increase was observed when compared to the control group (P < 0.001).
Patients with skin type II and III, in bimatoprost users, and patients with skin type III, in latanoprost users, had statistically significant
hyperpigmentation (P < 0.001) after the third month of therapy. During follow-up, no lacrimal drainage system obstruction was seen.
Conclusion: Topical bimatoprost therapy causes more periocular changes than latanoprost therapy. Thus, in unilateral cases, patients
should be well informed about these probable changes before therapy.
Key words: Bimatoprost, eyelids, lacrimal drainage, latanoprost

1. Introduction
In ophthalmology practice, topical prostaglandin
analogues are often used in antiglaucomatous treatment.
The potent efficacy, ease of use, and single dose application
of these drugs make them advantageous over other medical
therapy agents in glaucoma. They decrease the intraocular
pressure by 20%–35%, increasing the uveoscleral outflow
(1).
Despite the advantages mentioned above, numerous
side effects of prostaglandin analogues are reported in the
literature. Indeed, conjunctival hyperemia (2,3), increased
iris pigmentation (4–6), hypertrichosis (7–10), periocular
hyperpigmentation (11,12), and poliosis (13) are common
side effects of these drugs. In addition, uncommon as they
are, cystoid macular edema, herpetic keratitis activation,
and lash ptosis are observed (6). On top of all this,
particularly in bimatoprost use, periorbital fat atrophy,
deepening in upper eyelid sulcus, and regression in
dermatochalasis have been recently reported (14,15).
Few studies exist in the literature examining eyelid
motility and position in prostaglandin use. In recent years,
these orbital and adnexial changes have been described
* Correspondence: mzkarslioglu@gmail.com

under a separate heading, ‘prostaglandin associated
periorbitopathy’ (16).
The purpose of the present study was to evaluate
the periocular changes due to topical bimatoprost and
latanoprost therapy and to investigate its effects on the
lacrimal drainage system.
2. Materials and methods
A total of 121 eyes of 69 participants were examined
between May 2009 and February 2011 at Ankara University
Faculty of Medicine, Department of Ophthalmology. Of
the 43 patients, 21 patients (35 eyes) received bimatoprost
(0.03%) therapy, and 22 patients (34 eyes) latanoprost
(0.005%) therapy. The remaining 26 participants (52
eyes) were healthy and constituted the control group. The
control group and glaucoma patients were selected from
the outpatient polyclinic and glaucoma sections. All of the
participants were Turkish. Informed consent, including a
detailed explanation of the procedures, was obtained for
every patient in the experiment and control groups. The
study was conducted in accordance with the principles of
the Declaration of Helsinki.
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Our study was a prospective, comparative, openlabel, nonrandomized study of the effect of two different
prostaglandins on periocular measures. All participants
were examined before the prostaglandin therapy and
then at the first, third, sixth, and twelfth months of the
therapy. On ophthalmological examination, the anterior
and posterior segments of all the subjects were evaluated,
and intraocular pressure (IOP) was measured with
Goldmann applanation tonometry. Criteria for inclusion
in normal subjects were having an IOP less than 22
mmHg, normal visual fields, no evidence of glaucomatous
changes in the optic disc, and no history of glaucoma or
ocular hypertension in first-degree relatives. On every
examination, palpebral fissure height, upper eyelid crease,
and levator function were measured by a ruler and by
the same researcher. Upper eyelid sulcus asymmetry was
noted when observed. Periocular hyperpigmentation and
deepening of upper eyelid sulcus were checked at every
visit. The close-up photographs were taken by the same
researcher using the same camera. The parameters were
evaluated by a second researcher who was blinded as to
whether the patients had had the therapy or not.
The Fitzpatrick Skin-Type Chart was used to assess the
genetic disposition, reaction to sun exposure, and tanning
habits of the participants (17). By using this questionnaire,
the skin type can be quickly and easily determined by
adding up the score for each question. It entails six skintype categories: Type I, highly sensitive, always burns,
never tans; Type II, fairly sensitive, burns easily, tans
minimally; Type III, sun sensitive skin, sometimes burns,
slowly tans to light brown; Type IV, minimally sensitive,
burns minimally, always tans to moderate brown; Type V,
fairly insensitive skin, rarely burns, tans well; Type VI, sun
insensitive, never burns, deeply pigmented. For example,
pale skinned, fair haired Caucasians can be classified as
Type II, darker Caucasians as Type III, and Mediterraneantype Caucasians and some Hispanics as Type IV.
To investigate the effects of the prostaglandin analogue
therapy on the lacrimal drainage system, lacrimal
system irrigation was performed in all patients at each
examination.
All applicable institutional and governmental
regulations were followed concerning the ethical use of
human volunteers in this research.
2.1. Statistical analysis
Definitive data for continuous variables were estimated by
mean ± standard deviation (SD) or median (minimum–
maximum). Discrepant variables were processed by means
of the Mann–Whitney U test, Pearson’s chi-square test,
or Fischer’s exact chi-square test. The periocular changes
observed during the follow-up were qualified according to
presence/absence. To analyze these parameters, Cochran’s
test (with the Bonferroni procedure) was used. P < 0.025
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and P < 0.008 values were significant for the results. The
data were analyzed using SPSS version 15.0. In addition,
for the potential changes in eyelid motility and position
between the groups throughout the follow-up, a statistical
model was established, and mixed effect analysis of
variance (ANOVA) test was used. ANOVA is a tool used
to separate the analyzed variance in a specific variable into
components attributable to different sources of variation.
Our study uses this model, which is one of the functions of
XLSTAT 2006 for Microsoft Excel. P < 0.05 was significant
for the results.
3. Results
A total of 121 eyes of 69 participants (43 patients, 26 healthy
controls) were classified into three groups. Group 1 was
composed of 35 eyes of 21 patients on bimatoprost, Group
2 was composed of 34 eyes of 22 patients on latanoprost,
and Group 3 included 52 eyes of 26 healthy controls.
Table 1 shows the analysis of participants according to
demographic data, diagnosis, and skin type. There was no
significant difference between the groups in terms of age
(P = 0.163), sex (P = 0.884), or skin type distribution (P
= 0.369).
Palpebral fissure and levator function changes
recorded during the follow-up were insignificant in all
groups (in Group 1, P = 0.086, P = 0.348, respectively; in
Group 2, P = 0.592, P = 0.455, respectively). In terms of
upper eyelid crease, in Group 1, a statistically significant
increase was observed compared to the control group (P
< 0.001). However, in patients who used latanoprost, there
was no significant change (P = 0.297). Tables 2 and 3 show
the comparison of eyelid position and motility in subjects
on prostaglandin therapy and healthy controls.
At the end of the follow-up, significant periocular
changes including deepening of upper eyelid sulcus and
periocular hyperpigmentation were found in patients who
used bimatoprost (0.03%). They became obvious at the
3rd month of therapy (P < 0.001). However, in latanoprost
(0.005%) use, only periocular hyperpigmentation
formation was statistically significant, which occurred at
the 3rd month of therapy (P < 0.001).
This study also investigated the potential relation
between periocular hyperpigmentation and skin types. A
statistically significant increase in pigmentation took place
in Group 1, the patients with skin types II and III (P <
0.001), and in Group 2, patients with skin type III (P <
0.001), after the 3rd month of therapy. Tables 4 and 5 show
this relationship.
Lacrimal drainage system irrigation was performed in
every patient before and after the treatment. During the
follow-up, no lacrimal drainage system obstruction was
recorded in this series.
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Table 1. Analysis of patients on topical prostaglandin analogue and healthy controls according to demographic data, diagnosis, and skin
type.
Group 1
N = 21 (30.4%)

Group 2
N = 22 (31.9%)

Group 3
N = 26 (37.7%)

Mean age
Mean age ± SD
Median / (range)

63.9 ± 9.3
66 / (46–78)

58.1 ± 1 1.6
60.5 / (37–76)

59.1 ± 10.6
60.5 / (40–79)

0.163

Sex
Female
Male

12 (57.1%)
9 (42.9%)

12 (54.5%)
10 (45.5%)

16 (61.5%)
10 (38.5%)

0.884

Diagnosis
POAG
PXG
OHT

14 (40%)
17 (48.6%)
4 (11.4%)

19 (55.9%)
10 (29.4%)
5 (14.7%)

-

Skin type
Type II
Type III
Type IV

6 (28.6%)
13 (61.9%)
2 (9.5%)

2 (9.1%)
18 (81.8%)
2 (9.1%)

5 (19.2%)
16 (61.5%)
5 (19.2%)

P value
a

b

b

0.000

b

0.369

Mann–Whitney U test; b Pearson chi-square test; N, number; SD, standard deviation; P < 0.05 is statistically significant.
POAG, primary open-angle glaucoma; PXG, pseudoexfoliative glaucoma; OHT, ocular hypertension.

a

Table 2. Comparison of patients on bimatoprost (0.03%) therapy and healthy controls throughout
follow-up in terms of eyelid position and motility.
Bimatoprost (0.03%) therapy
(N = 35)

Healthy controls
(N = 52)

P value

PF change (mm) ± SE

0.83 ± 0.18

–0.06 ± 0.15

0.086

ULC change (mm) ± SE

1.17 ± 0.36

–0.06 ± 0.15

<0.0001

LF change (mm) ± SE

–0.26 ± 0.27

0.32 ± 0.22

0.348

a

Mixed effect ANOVA test; P < 0.05 is statistically significant; SE, standard error.
PF, palpebral fissure; ULC, upper eyelid crease; LF, levator function, N, number.

a

Table 3. Comparison of patients on latanoprost (0.005%) therapy and healthy controls throughout
follow-up in terms of eyelid position and motility.
Latanoprost (0.005%)
therapy (N = 34)

Healthy controls
(N = 52)

P value

PF change (mm) ± SE

0.44 ± 0.18

–0.06 ± 0.15

0.592

ULC change (mm) ± SE

0.29 ± 0.37

–0.06 ± 0.15

0.297

LF change (mm) ± SE

0.38 ± 0.27

0.32 ± 0.22

0.455

a

Mixed effect ANOVA test; P < 0.05 is statistically significant; SE, standard error.
PF, palpebral fissure; ULC, upper eyelid crease; LF, levator function; N, number.
a
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Table 4. The relationship between periocular hyperpigmentation and skin type among bimatoprost (0.03%) users.

Skin type

Topical bimatoprost (0.03%) use (N = 35)
a

Periocular hyperpigmentation (+)

Periocular hyperpigmentation (–)

P value

Type II

7 (20%)

3 (8.6%)

0.000 (3rd Mo)

Type III

11 (31.4%)

11 (31.4%)

0.000 (3rd Mo)

Type IV

3 (8.6%)

0

0.037

a

Cochran’s test (with Bonferroni procedure); P < 0.008 is statistically significant; N, number; Mo, month.

Table 5. The relationship between periocular hyperpigmentation and skin type among latanoprost (0.005%) users.

Skin type

Topical latanoprost (0.005%) use (N = 34)
a

Periocular hyperpigmentation (+)

Periocular hyperpigmentation (–)

P value

Type II

1 (2.9%)

1 (2.9%)

0.406

Type III

8 (23.5%)

20 (58.8%)

0.000 (3rd Mo)

Type IV

0

4 (11.8%)

-

Cochran’s test (with Bonferroni procedure); P < 0.008 is statistically significant; N, number; Mo, month.

a

4. Discussion
Clinical pharmacokinetic studies on male cynomolgus
monkeys have proved that, after 0.1% bimatoprost
application, ocular tissue concentration of eyelids were
2000 times greater than aqueous humor and were 16
times greater than iris and ciliary body concentration
(18). Therefore, this information is of great importance
in periorbital prostaglandin absorption in topical
antiglaucomatous therapy.
The deepening of upper eyelid sulcus and regression
of dermatochalasis were first reported by Peplinski et al.
in three patients who used unilateral topical bimatoprost
therapy (19). They reported these side effects throughout
the first and ninth months of the treatment. Additionally,
the authors observed the reversibility of these effects in
one patient, 6 weeks after the cessation of the therapy.
Prostaglandin associated periorbitopathy was first
defined by Filippopoulos et al. in 2008, including periorbital
fat atrophy, deepening upper eyelid sulcus, and regression
of dermatochalasis (16). They investigated 5 glaucoma
patients using unilateral bimatoprost for 7 months and
4 years, and observed these periocular changes in all
patients. The authors also observed that these changes
were reversed after the termination of therapy at the 3rd
or 6th months.
Periorbital fat atrophy was initially documented by
Jayaprakasam et al. on magnetic resonance imaging in a
patient who used unilateral bimatoprost for 2 years (14). This

928

study recorded the deepening of upper eyelid sulcus and 2
mm relative enophthalmos by fat atrophy. Nine months
after the cessation of the treatment, fat atrophy was almost
completely reversed. According to investigators, the inhibition
of adipocyte production and differentiation, and production
by prostaglandins may be responsible for the resultant fat
atrophy. Therefore, the reversal of fat atrophy after cessation
may be due to the removal of this inhibiting agent.
Histological changes in prostaglandin analogue users
were first shown by Park et al. in 2011 by orbital fat tissue
biopsy (15). In addition to bimatoprost, they studied
latanoprost and travoprost. They observed deep superior
sulcus in all three prostaglandin groups and compared the
orbital fat tissue between the treated and untreated eyes.
A careful analysis of histological preparations revealed
decreased intracellular lipid volume in adipocytes. Because
of the displacement of adipocyte nuclei, a relative increase
in mean adipocyte density per unit area was observed in
three prostaglandin analogue-treated eyes.
Tan et al. reported three patients who had latanoprostinduced prostaglandin associated periorbitopathy via
photo documentation, retrospectively. The deepening
of upper eyelid sulcus, blepharoptosis, involution of
dermatochalasia, and flattening of lower eyelid bags were
seen after a mean consumption time of 6 years (3 to 8
years). The researchers drew attention to the lower risk and
longer latency of onset of these changes with latanoprost
than with bimatoprost or travoprost (20).
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In the present study, 34.3% of the patients on
bimatoprost therapy (P < 0.001) and 2.9% of the patients
on latanoprost therapy (P = 0.406) developed upper eyelid
sulcus deepening. Because the therapy continued, it was
not possible to observe reversibility.
Altieri et al. examined 182 patients who were on
bilateral prostaglandin therapy and 191 age-matched
healthy controls (21). The patients and healthy controls
did not differ significantly according to eyelid position or
motility. They also investigated bimatoprost, latanoprost,
and travoprost separately and found no significant
difference among the groups.
Conversely, Wang et al. reported a patient with
right upper eyelid ptosis 2 months after starting topical
bimatoprost (0.03%) therapy. Evidently, the patient’s
right levator muscle became less able to function. After
the termination of therapy, levator muscle resection was
performed. The authors noted that this side effect may
not be completely reversible even after the therapy was
terminated (22).
The results of our study revealed no significant
change in terms of vertical palpebral fissure height or
levator function (P = 0.086 and P = 0.348, respectively)
in bimatoprost or latanoprost therapy (P = 0.592 and P
= 0.455, respectively) compared to the control group.
A significant increase in the upper eyelid crease was
determined in patients who used bimatoprost (P < 0.001).
This change was insignificant in the latanoprost group (P
= 0.297).
Prostaglandins are potent stimulators in melanogenesis
(23). After melanin is produced in dermal melanocytes, it
is transferred to keratocytes neighboring the epidermal
basal membrane (24). Melanin laden keratocytes are
thrown out by the epidermal cell cycle (25). Thus, the
normal epidermal cell cycle accounts for the reversibility
of pigmentary changes.
Periocular hyperpigmentation due to topical
prostaglandin use was first reported by Wand et al. in
a 75-year-old woman who had undergone binocular
latanoprost therapy for 15 months (12). Two months after
the cessation of the treatment, periocular pigmentation
significantly decreased.
In our study, the incidence of periocular
hyperpigmentation was 60% (P < 0.001) in bimatoprost
users and 26.5% (P < 0.001) in latanoprost users.
The research also focused on the potential relation
between the periocular hyperpigmentation and skin types.
Of the 69 participants, 13 had (18.8%) skin type II, 47
(68.1%) skin type III, and 9 (13%) skin type IV. In Group

1, skin type II and III (P < 0.001) patients, and in Group
2, skin type III (P < 0.001) patients displayed a statistically
significant increase in pigmentation after 3 months of
therapy. To the best of our knowledge, this is the first
study using the Fitzpatrick Skin-Type Chart to analyze
the relation between the periocular pigmentation and skin
type of patients using topical prostaglandin analogues.
Additionally, our study is the first prospective research
to investigate the effects of topical prostaglandin therapy on
lacrimal drainage system. It seems that a single article exists
by Artunay et al. about nasolacrimal canal obstruction
and antiglaucomatous therapy (26). They analyzed the
participants retrospectively. Two hundred and five eyes
of 110 glaucoma patients and 184 eyes of 94 untreated
glaucoma suspects were evaluated. In the treatment
group using an antiglaucomatous agent, the incidence
of nasolacrimal canal obstruction was 13.7%, and in the
untreated group it was 7.1%. The difference between the
groups was statistically significant (P < 0.05). The authors
also reviewed patients who suffered from nasolacrimal
canal obstruction according to antiglaucomatous drug
subtypes. Of the patients who had nasolacrimal canal
obstruction, 28.5% were using timolol maleate, 21.5%
were using prostaglandin analogues, and 50% were using
a combination of them. The time that elapsed from the
initial treatment to the nasolacrimal canal obstruction was
estimated to be 4.8 ± 2.4 years.
No lacrimal drainage system obstruction developed
during the follow-up phase of our study. Studies with
larger series and longer follow-up are needed for more
conclusive results.
In conclusion, topical bimatoprost therapy causes
more marked periocular changes than topical latanoprost
therapy. For instance, our study revealed a significant
deepening of upper eyelid sulcus and periocular
hyperpigmentation after bimatoprost use (P < 0.001).
Moreover, upper eyelid crease significantly increased in the
bimatoprost group (P < 0.001). Finally, in the latanoprost
group, significant periocular hyperpigmentation (P <
0.001) was observed.
As a result, ophthalmologists, particularly glaucoma
specialists should be aware of the potential periocular
changes due to topical prostaglandin analogues and
should inform their patients properly about it. Especially
when treating unilateral cases, physicians should behave
much more cautiously.
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